Day: June 19, 2020

TORONTO, June 19, 2020 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX-V: LAB) (“LabGold” or the “Company”) is pleased to announce that it has closed the previously announced (see news release dated May 28, 2020) non-brokered private placement of 4,000,000 flow through units (the “FT units”) at a price of $0.25 per FT Unit (the “Flow Through Offering”) for gross proceeds to LabGold of $1,000,000. Each FT Unit is comprised of one flow through share (the “FT Shares”) and one non-flow through share purchase warrant, with each warrant exercisable to acquire a Common Share at C$0.30 until June 18, 2022.The gross proceeds from the issuance of the FT Shares will be used for “Canadian exploration expenses” and will qualify as “flow-through mining expenditures” (the “Qualifying Expenditures”), as those terms are defined in the Income Tax Act...

CALGARY, Alberta, June 19, 2020 (GLOBE NEWSWIRE) — As previously announced by Delphi Energy Corp. (“Delphi” or the “Company”), the Company is relying on exemptive relief granted by Canadian securities regulatory authorities that allows it to delay the filing of its interim financial report for the interim period ended March 31, 2020 as required by section 4.4 of National Instrument 51-102 and related management’s discussion & analysis as required by subsection 5.1(2) of National Instrument 51-102 (collectively, the “Q1 Filings”) and estimates that the Q1 Filings will be available for filing on or about June 24, 2020. Until such time as these filings are made, Delphi’s management and other insiders are subject to a trading blackout that reflects the principles contained in section 9 of National Policy 11-207 – Failure-to-File...

LAVAL, Québec, June 19, 2020 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the FDA has provided Acasti with a written response to its Type C Meeting request and briefing package.The FDA confirmed that it will require pivotal efficacy analyses for TRILOGY 2 to be performed on the full Intent to Treat (ITT) population as contemplated in the original Statistical Analysis Plan (SAP), and they supported the conduct of post-hoc analyses in TRILOGY 1 for exploratory purposes. Consistent with the Company’s prior disclosures, and depending on the outcome of TRILOGY 2,...

Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBCImprovements in other quality-of-life parameters also observedNEWARK, Calif., June 19, 2020 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced new data from a previously completed open-label Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). These data were made available as an electronic presentation through the Digestive Disease Week® (DDW®) 2020 Online Education program. Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) that has demonstrated anti-cholestatic...

SAN JOSE, Calif., June 19, 2020 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has entered into a record, three-year strategic cancer screening collaboration contract with Beijing Yuan Jian Health Management Co., Ltd. in China, which has been a client of the Company for the past two years. This contract contains a minimum of 76,000 paid cancer screening tests, including at least 6,000 paid tests in 2020, 25,000 paid tests in 2021, and 45,000 paid tests in 2022. The total value of the contract is slightly over US$3 million and exceeds the previous contract by more than double the number of paid tests per year.  AnPac Bio’s CEO,...

SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 10:00 a.m. ET.A live webcast of the presentation will be available at http://ir.retrophin.com/events and an archived replay will be accessible for up to 30 days.About RetrophinRetrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading...

VAL-D’OR, Quebec, June 19, 2020 (GLOBE NEWSWIRE) — Cartier Resources Inc. (TSX-V: ECR) (“Cartier” or the “Company”) announces that at its annual general meeting held on June 18th, 2020 the following persons were elected as directors of Cartier:The stock option plan of the Company (the “Plan”) as described in the Management Information Circular (the “Circular”) was approved by the shareholders at the meeting. The maximum number of shares issuable under the Plan to represent a maximum of 10% of the shares issued and outstanding from time to time (on a non-diluted basis).The proposal to appoint KPMG LLP as auditors of the Company as presented in the Circular was approved by the shareholders at the meeting.Following the annual meeting, the Board of Directors named the following persons as officers of the Company:Philippe Cloutier, P.Geo.,...

VAL-D’OR, Québec, 19 juin 2020 (GLOBE NEWSWIRE) — Ressources Cartier Inc. (TSX-V: ECR) (« Cartier » ou la « Société ») annonce que, suite à son assemblée générale annuelle tenue le 18 juin 2020, les personnes suivantes ont été élues à titre d’administrateurs de Cartier :Le régime d’options d’achat d’actions de la société (le « régime ») tel que décrit à la circulaire de sollicitation de procurations (la « circulaire ») a été approuvée par les actionnaires à l’assemblée. Le nombre maximal d’actions qui peuvent être émises en vertu du régime est de 10 % du nombre d’actions émises et en circulation de temps à autre (sur une base non diluée).  La proposition de nomination de KPMG. s.r.l., S.E.N.C.R.L. à titre d’auditeur indépendant de la société, telle que décrite à la circulaire, a été approuvée par les actionnaires à l’assemblée.Suite...

Growth Capital To Fuel Surging Revenue Growth in 2020NEW YORK and TORONTO, June 19, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality for eCommerce, AR learning applications, and AR-enhanced virtual events is pleased to announce that it has closed a private placement of 1,528,036 units priced at the market price of $2.10 per unit (the “Units”) for gross proceeds of $3,208,875 (the “Offering”). Each Unit consists of one common share and one half share purchase warrant exercisable at $3.00 per share for a period of two years (the “Warrants”) and subject to acceleration provisions. The use of proceeds includes: growing sales and engineering teams, pursuing strategic M&A opportunities, and for general working capital purposes.Kashif Malik CFO of...